Prescription drugs and self-care products

Orion has a wide range of primary healthcare prescription drugs and other products for treatment and prevention of the commonest illnesses. Our portfolio consists of a range of almost 400 products.

Our product portfolio includes:

  • Proprietary drugs developed by Orion itself
  • Substitutable generic drugs
  • Patented drugs licensed from other pharmaceutical companies
  • Self-care products such as non-prescription medicines, basic ointments and vitamins

Our own proprietary drugs

Human pharmaceuticals developed by Orion:

Drug name

Active pharmaceutical ingredient

Indication

Launched

dexdor®

dexmedetomidine

intensive care sedative

2011

Stalevo®

levodopa, carbidopa, entacapone

Parkinson’s disease

2003

Simdax®

levosimendan

acute decompensated heart failure

2000

Precedex®

dexmedetomidine

intensive care sedative

1999

Comtess®/Comtan®

entacapone

Parkinson’s disease

1998

Fareston®

toremifene

breast cancer

1988

Orion’s discoveries also include the Easyhaler® metered-dose dry powder inhaler for treatment of asthma and chronic obstructive pulmonary disease. The medicines used in Easyhaler devices are generic. The Easyhaler product family includes:

Drug name

Active pharmaceutical ingredient

Indication

Launched

Bufomix Easyhaler®

budesonide, formoterol

asthma and chronic obstructive pulmonary disease

2014

Formoterol Easyhaler®

formoterol

asthma and chronic obstructive pulmonary disease

2004

Budesonide Easyhaler®

budesonide

asthma and chronic obstructive pulmonary disease

2002

Beclomet Easyhaler®

beclomethasone

asthma and chronic obstructive pulmonary disease

1994

Buventol Easyhaler®

salbutamol

asthma and chronic obstructive pulmonary disease

1993

Orion’s own proprietary products also include Domitor® (medetomidine), Dexdomitor® (dexmedetomidine) and Domosedan® (detomidine) sedatives used by veterinarians, and the antagonist to them Antisedan® (atipamezole). More information on these products can be found on the Animal Health business division’s web page.